within Pharmacolibrary.Drugs.ATC.R;

model R03AK12
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0016666666666666668,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.16,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.4,
    k12             = 85,
    k21             = 85
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R03AK12</td></tr><td>route:</td><td>inhalation</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>A fixed-dose combination of salmeterol, a long-acting beta-2 adrenergic agonist (LABA), and budesonide, an inhaled corticosteroid (ICS). This combination is used as a maintenance treatment for asthma and chronic obstructive pulmonary disease (COPD) to reduce inflammation and bronchodilation. It is approved and commonly used today for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for healthy adult subjects after inhalation based on published data for individual components; no direct published PK model for the fixed-combination inhaler product exists.</p><h4>References</h4><ol><li><p> (2020). Drugs for COPD. <i>The Medical letter on drugs and therapeutics</i> 62(1606) 137–144. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32960872/&quot;>https://pubmed.ncbi.nlm.nih.gov/32960872</a></p></li><li><p>Popov, TA, et al., &amp; Vanderbist, F (2016). Budesonide/salmeterol in fixed-dose combination for the treatment of asthma. <i>Expert review of respiratory medicine</i> 10(2) 113–125. DOI:<a href=&quot;https://doi.org/10.1586/17476348.2016.1133302&quot;>10.1586/17476348.2016.1133302</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26677916/&quot;>https://pubmed.ncbi.nlm.nih.gov/26677916</a></p></li><li><p>Spencer, CM, &amp; Jarvis, B (1999). Salmeterol/fluticasone propionate combination. <i>Drugs</i> 57(6) 933–943. DOI:<a href=&quot;https://doi.org/10.2165/00003495-199957060-00010&quot;>10.2165/00003495-199957060-00010</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10400406/&quot;>https://pubmed.ncbi.nlm.nih.gov/10400406</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R03AK12;
